CLARIVATE PLC — Form 8-K/A
Filed October 13, 2026 · analyzed by the 8-K Agent
8-K/A
▲ Likely positive
significance 68/100
What the filing says
On October 6, 2026, Clarivate completed the sale of its Life Sciences & Healthcare (LS&H) business to an Altaris affiliate for $600M total consideration: $488.4M cash at close (net of costs), a $75M unsecured senior note, and $25M deferred cash due by January 31, 2028. LS&H generated ~$389.8M in revenues (16% of total) and $211.4M of operating income in 2025; the divestiture reduces Clarivate to a smaller, more focused business. Clarivate used $575M of proceeds ($488.4M from sale + $11.6M company cash + $75M additional company cash in September 2026) to redeem and tender for debt, reducing interest expense and leverage.
Why this rating
Major strategic portfolio shift (16% of 2025 revenue removed) materially reshapes Clarivate; ~46% of $1.3B market cap in total consideration is material. Debt reduction improves balance sheet; LS&H gains of ~$211M operating income may mask profitability loss, but proceeds deploy to deleveraging. Significant reorientation—not transformational—for $1.3B company.
See more from October 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.